Clinical Research Directory

Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

Sponsor: Sangamo Therapeutics

Summary

This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.

Official title: Long-Term Follow-Up of Patients Who Have Received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg Therapy, TX200-TR101) in a Prior Clinical Study

Key Details

Conditions

Interventions

Locations (5)